Drug Trial Radar · NCT06172257
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)
Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
401
Actual
Start
Mar 15, 2024
Primary completion
Apr 2, 2026
Study completion Apr 2, 2026
Sponsor
- Lead sponsor
- OculisIndustry
- Sponsor type
- Industry
- First posted
- Dec 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of OCS 01 as compared to Vehicle in participants with Diabetic Macular Edema (DME).
Conditions
- Diabetic Macular Edema
Interventions
Dexamethasone ophthalmic suspension (OCS-01)Drug
Participants will be dosed with one eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase).
VehicleDrug
Participants will be dosed with one eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change from Baseline in BCVA (Best Corrected Visual Acuity)Time frame: Week 52
Locations
62 sites in 4 countries. Site status is shown where the registry gives one.
Associated Retina Consultants
Gilbert, Arizona
Associated Retina Consultants
Phoenix, Arizona
Retinal Consultants of Arizona - Phoenix North
Phoenix, Arizona
California Retina Consultants
Bakersfield, California
Retina Associates of Southern California
Huntington Beach, California
Stanford Byers Eye Institute
Palo Alto, California
Retinal Consultants Medical Group, Inc
Sacramento, California
Retinal Consultants Medical Group
Sacramento, California
California Retina Consultants
Santa Barbara, California
Macula Retina Vitreous Center
Torrance, California
Retina Specialists of Colorado
Denver, Colorado
Eye Care Center of Northern Colorado
Longmont, Colorado
Sibia Eye Institute
Boynton Beach, Florida
Blue Ocean Clinical Research
Clearwater, Florida
Advanced Research
Coral Springs, Florida
Retina Group of Florida
Fort Lauderdale, Florida
East Coast Institute for Research
Jacksonville, Florida
Retina Consultants of Southwest Florida
Naples, Florida
Marietta Eye Clinic
Marietta, Georgia
Georgia Retina
Peachtree City, Georgia
Illinois Retina Associates
Oak Park, Illinois
Cumberland Valley Retina Consultants
Hagerstown, Maryland
Mid Atlantic Retina Specialists
Hagerstown, Maryland
Ophthalmic Consultants of Boston
Boston, Massachusetts
Mississippi Retina Associates
Jackson, Mississippi
Sierra Eye Associates
Reno, Nevada
VitreoRetinal Consultants of NY
Hauppauge, New York
Island Retina
Shirley, New York
Vitreoretinal Consultants of NY
Westbury, New York
Erie Retina Research
Erie, Pennsylvania
Vision Research Solutions in Philadelphia
Philadelphia, Pennsylvania
Palmetto Retina Center
West Columbia, South Carolina
Charles Retina Institute
Germantown, Tennessee
Tennessee Retina
Nashville, Tennessee
Retina Consultants of Texas
Bellaire, Texas
Star Retina
Burleson, Texas
Houston Eye Associates, North Loop
Houston, Texas
Austin Retina Associates
Round Rock, Texas
San Antonio Eye Center - Downtown Clinic
San Antonio, Texas
Medical Center Ophthalmology Associates
San Antonio, Texas
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.